- Intensive systolic blood pressure control was associated with lower major adverse cardiovascular event risk.
- Benefit was observed across cardiovascular-kidney-metabolic syndrome stages.
- Absolute risk reduction increased with higher baseline cardiometabolic risk.
- Adverse events increased modestly but did not outweigh cardiovascular benefit.
- Findings support lower blood pressure targets in appropriately selected high-risk patients.
Source: JAMA Network Open
